Clinical Trial of Favipiravir Treatment of Patients With COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-07

Study Completion Date

2020-12-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To verify that the efficacy of favipiravir exceeds that of the actual supportive care (symptomatic therapy) in SARS-CoV-2 infected patients (COVID-19 patients) with mild pneumonia, using the time required to improve clinical symptoms as the primary endpoint.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19

NCT04358549

COVID-19

COMPLETED PHASE2

Study to Assess the Efficacy and Safety of Favipiravir-HU

NCT04940871

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

TERMINATED PHASE2

Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19

NCT04336904

COVID-19

UNKNOWN PHASE3

Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19

NCT05014373

Covid19

UNKNOWN PHASE3

Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19

NCT04346628

Sars-CoV2 COVID-19

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group Avigan

Favipiravir from Day1 + Supportive care (symptomatic therapy) a regimen of 3600 mg (1800 mg twice a day orally) loading dose on Day1 followed by 1600 mg maintenance dose (800 mg twice a day orally) on Day2 to Day14.

Group Type EXPERIMENTAL

Favipiravir

Intervention Type DRUG

Name: AVIGAN Generic name: Favipiravir Content: T-705a tablets \[200\]

Group Control

Supportive care (symptomatic therapy)

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Favipiravir

Name: AVIGAN Generic name: Favipiravir Content: T-705a tablets \[200\]

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18 to 74 years (at the time of informed consent)
2. Male or female
3. Patients who meet all of the following three criteria at the time of enrolment:

1. SARS-CoV-2-positive patients as measured by rtPCR by nasopharyngeal sampling
2. Moderate patients with radiological evidence of pneumonia in the lung at the time of enrolment (RTG, CT, or UH), clearly described by the radiologist following the imaging examination. (The diagnosis of the finding should clearly include the presence of pneumonia to any extent, localization, and extent)
3. Body temperature 37,5°C or more
4. Patient requires hospitalization during the treatment period (obligation to stay in the hospital for whole treatment period, 14 days)
4. For premenopausal females, patients who have been confirmed to be negative on a pregnancy test before administration of the study drug
5. Signed informed consent by the patient or by the legal representative -

Exclusion Criteria

1. Body temperature of 37.5 °C or higher for more than 10 days after the onset of elevated body temperature
2. Patients with SpO2 less than 95%
3. Patient requires supportive oxygen therapy
4. Patients who show increased procalcitonin levels before the start of the study drug administration and are suspected to have concurrent bacterial infection
5. Patients with proven concomitant systematic fungal infection prior to initiation of study drug.
6. Patients with concurrent congestive heart failure (NYHA III-IV)
7. Patients with severe hepatic impairment equivalent to Grade C on Child-Pugh classification
8. Patient with renal impairment requiring dialysis.
9. Patients with disturbed consciousness such as disturbed orientation.
10. Pregnant or possibly pregnant patients.
11. Female patients who are woman of childbearing potential and unable to consent to the use of dual contraception from the start of favipiravir administration to 30 days after the end of favipiravir administration. Dual contraception is a combination of two of the following: Barrier method of contraception: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide; IUD; Hormone-based contraceptive; Tubal ligation
12. Male patients whose are unable to consent to the use of the barrier method of contraception (condom) from the start of favipiravir administration to 90 days after the end of favipiravir administration. Male patients who are planning to donate sperm from the start up until 90 days after the end of favipiravir administration.
13. Female patients who intend to breastfeed from the start of favipiravir administration until 14 days after discontinuation of favipiravir administration
14. Patients with herditary xanthinuria
15. Patients who have hyperuricemia (\> 1 mg/dL) or xanthine urinary calculi
16. Patients with a history of gout or on treatment for gout or hyperuricemia
17. Patients receiving immunosuppressants
18. Patients who received interferon-alpha or drugs with reported antiviral activity against SARS-CoV-2 (hydroxychloroquine sulfate, chloroquine phosphate, lopinavir-ritonavir combination, ciclesonide, nafamostat mesylate, camostat mesylate, remdesivir, etc.) within 9 days after fever onset (37.5°C or more)
19. Patients in whom this episode of infection is a recurrence or a reinfection with the SARS-CoV-2 infection
20. Patients who have previously been treated with favipiravir (T-705a)
21. Other patients judged ineligible by the investigator, sub-investigator, or assigned physician.

\-

Minimum Eligible Age

18 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No